Serum Androgens as Predictive Biomarkers: Results From a Randomized Clinical Trial Comparing Enzalutamide and Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer.
Klara K TernovMikkel FodeJens SønksenRasmus BisbjergHenriette LindbergGanesh PalapattuOla BrattPeter B ØstergrenPublished in: Clinical genitourinary cancer (2024)
Pre-treatment serum testosterone levels may be a clinically useful biomarker for predicting mCRPC treatment responses and guiding treatment selection.